Summary
Biogen Idec Inc. (BIIB) announced the early termination of its stockholder rights plan, also known as a poison pill, effective January 30, 2009. Originally set to expire in July 2011, the termination means that the rights attached to each share of common stock, which allowed holders to purchase preferred stock under specific circumstances, will no longer be outstanding or exercisable. This action by the Board of Directors suggests a potential shift in the company's approach to corporate governance and defense against hostile takeovers. In addition to terminating the rights plan, the Board also recommended the approval of a bylaw amendment for a majority voting standard in uncontested director elections at the upcoming 2009 Annual Meeting of Stockholders. This move indicates a commitment to enhancing shareholder democracy and responsiveness by requiring director nominees to secure a majority of the votes cast in uncontested elections.
Key Highlights
- 1Biogen Idec Inc. is terminating its stockholder rights plan (poison pill) early, effective January 30, 2009.
- 2The rights plan was originally scheduled to expire on July 26, 2011.
- 3Upon termination, all unredeemed rights will cease to be outstanding and exercisable.
- 4The Board of Directors approved an amendment to the existing Rights Agreement to facilitate this early termination.
- 5The company's Board also plans to recommend a bylaw amendment for majority voting in uncontested director elections at the 2009 Annual Meeting.
- 6This move towards majority voting aims to increase shareholder influence in director appointments.